Benzinga · Aug 28, 2026
BioNTech Stock Dips After BNT122-01 Trial Termination
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
NASDAQ · BNTX
BioNTech SE
Healthcare · Biotechnology
$102.08
Down-$0.85 (-0.83%)
Updated Aug 31, 2026, 7:30 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 23.08B
- P/E ratio
- -57.03
- Dividend yield
- 0.00%
- 52-week range
- $79.52 – $120.33
- Volume
- 3.07M
- Avg. volume
- 1.03M
Price performance
BNTX price history
1M range · 20 trading sessions · Daily adjusted prices
BNTX closed at $102.08 after 20 trading sessions, up 10.65% for the selected period.
- Last close
- $102.08
- Period change
- +10.65%
- Period low
- $91.19
- Period high
- $116.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $102.34 | $105.23 | $98.80 | $102.075 | 3.07M |
| Aug 27, 2026 | $111.69 | $112.81 | $110.25 | $111.40 | 1.55M |
| Aug 26, 2026 | $112.91 | $113.97 | $111.215 | $112.56 | 1.26M |
| Aug 25, 2026 | $113.88 | $116.87 | $113.405 | $114.05 | 1.36M |
| Aug 24, 2026 | $114.03 | $114.195 | $110.517 | $112.82 | 1.85M |
| Aug 21, 2026 | $110.92 | $120.33 | $110.89 | $116.57 | 2.96M |
| Aug 20, 2026 | $109.06 | $112.39 | $106.38 | $110.89 | 3.53M |
| Aug 19, 2026 | $109.29 | $116.00 | $107.18 | $113.12 | 8.78M |
| Aug 18, 2026 | $91.49 | $93.025 | $91.01 | $92.75 | 921.59K |
| Aug 17, 2026 | $93.22 | $93.76 | $91.23 | $91.60 | 443.53K |
| Aug 14, 2026 | $91.73 | $93.24 | $90.52 | $93.09 | 650.53K |
| Aug 13, 2026 | $92.89 | $93.20 | $91.69 | $92.12 | 988.54K |
| Aug 12, 2026 | $92.26 | $93.80 | $92.00 | $92.74 | 476.5K |
| Aug 11, 2026 | $92.84 | $93.23 | $92.035 | $92.80 | 705.98K |
| Aug 10, 2026 | $94.10 | $94.25 | $92.595 | $92.80 | 731.13K |
| Aug 7, 2026 | $91.90 | $94.27 | $91.57 | $93.67 | 1.43M |
| Aug 6, 2026 | $92.50 | $92.65 | $89.70 | $91.19 | 1.35M |
| Aug 5, 2026 | $91.42 | $92.96 | $90.40 | $92.18 | 1.7M |
| Aug 4, 2026 | $88.98 | $93.75 | $88.20 | $91.35 | 2M |
| Aug 3, 2026 | $91.01 | $94.41 | $89.50 | $92.25 | 1.12M |
Latest BNTX news
The latest Smart Investors Daily articles mentioning BNTX.
Stock researchCompany · Overview
BNTX research
Overview
Company profile and research snapshot.
Company profile
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $144.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
| Jul 8, 2026 | Morgan Stanley | Overweight | — |
| May 27, 2026 | UBS | Buy | — |
| May 22, 2026 | Bernstein | Market Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 28, 2026
BioNTech Says It Will Terminate Phase 2 BNT122-01 Trial Of Autogene Cevumeran In ctDNA-Positive Resected Colorectal Cancer After DSMB Identified Numerical Overall Survival Imbalance Between Arms; No New Safety Signals
https://www.sec.gov/Archives/edgar/data/1776985/000177698526000061/a991260828_bntxxcrcxenxfin.htm
Benzinga · Aug 27, 2026
QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax
FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.
Benzinga · Aug 27, 2026
FDA Approves Pfizer And BioNTech's Supplemental Biologics License Application For 2026-2027 COVID-19 Vaccine Formula
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
